Trimethoprim-sulfamethoxazole: Difference between revisions
From IDWiki
No edit summary |
(added some dosing guidelines) |
||
(2 intermediate revisions by the same user not shown) | |||
Line 16: | Line 16: | ||
! TMP |
! TMP |
||
! SMX |
! SMX |
||
+ | !Conversion |
||
|- |
|- |
||
+ | | Intravenous |
||
− | | Suspension |
||
− | | 8 mg/ml |
||
− | | 40 mg/ml |
||
− | |- |
||
− | | Injection |
||
| 16 mg/ml |
| 16 mg/ml |
||
| 80 mg/ml |
| 80 mg/ml |
||
+ | |10 mL |
||
+ | |- |
||
+ | | Oral suspension |
||
+ | | 8 mg/ml |
||
+ | | 40 mg/ml |
||
+ | |20 mL |
||
|- |
|- |
||
− | | SS tab |
+ | | Oral SS tab |
| 80 mg |
| 80 mg |
||
| 400 mg |
| 400 mg |
||
+ | |2 tabs |
||
|- |
|- |
||
− | | DS tab |
+ | | Oral DS tab |
| 160 mg |
| 160 mg |
||
| 800 mg |
| 800 mg |
||
+ | |1 tab |
||
|} |
|} |
||
− | * Conversion: 2 SS tabs = 1 DS tab = 20 mL oral suspension = 10 mL IV |
||
* Resistant Gram-negative infections |
* Resistant Gram-negative infections |
||
** [[Cystitis]]: 160 mg (1 SS tab) IV/PO q12h |
** [[Cystitis]]: 160 mg (1 SS tab) IV/PO q12h |
||
** Other infections: 8 to 12 mg/kg/day IV/PO divided q8-12h (max 960 mg total daily dose) |
** Other infections: 8 to 12 mg/kg/day IV/PO divided q8-12h (max 960 mg total daily dose) |
||
+ | *[[Nocardia]]: 10 mg/kg TDD |
||
+ | *[[Pneumocystis jirovecii]]: 15-20 mg/kg TDD |
||
+ | *CNS infections: 15-20 mg/kg TDD |
||
=== Oral Dosing === |
=== Oral Dosing === |
||
Line 51: | Line 58: | ||
{| class="wikitable" |
{| class="wikitable" |
||
! Weight (kg) |
! Weight (kg) |
||
− | ! Dose (IV) |
||
! Total dose TMP (mg/day) |
! Total dose TMP (mg/day) |
||
+ | ! Dose (IV) |
||
+ | !Dose (PO) |
||
|- |
|- |
||
| 40-49 |
| 40-49 |
||
+ | | 480 |
||
| 10 mL q8h |
| 10 mL q8h |
||
+ | |1 DS tab q8h |
||
− | | 480 |
||
|- |
|- |
||
| 50-64 |
| 50-64 |
||
+ | | 640 |
||
| 10 mL q6h |
| 10 mL q6h |
||
+ | |1 DS tab q6h, or 2 DS tabs q12h |
||
− | | 640 |
||
|- |
|- |
||
| 65-74 |
| 65-74 |
||
+ | | 720 |
||
| 15 mL q8h |
| 15 mL q8h |
||
+ | |3 SS tabs q8h |
||
− | | 720 |
||
|- |
|- |
||
| 75-99 |
| 75-99 |
||
+ | | 960 |
||
| 15 mL q6h |
| 15 mL q6h |
||
+ | |2 DS tabs q8h, or 3 SS tabs q6h |
||
− | | 960 |
||
|- |
|- |
||
| 100-129 |
| 100-129 |
||
− | | 20 mL q6h |
||
| 1280 |
| 1280 |
||
+ | | 20 mL q6h |
||
+ | |2 DS tabs q6h |
||
|} |
|} |
||
Line 79: | Line 92: | ||
{| class="wikitable" |
{| class="wikitable" |
||
! Weight (kg) |
! Weight (kg) |
||
− | ! Dose (IV) |
||
! Total dose TMP (mg/day) |
! Total dose TMP (mg/day) |
||
+ | ! Dose (IV) |
||
+ | !Dose (PO) |
||
|- |
|- |
||
| 40-44 |
| 40-44 |
||
− | | 10 mL q6h |
||
| 640 |
| 640 |
||
+ | | 10 mL q6h |
||
+ | |1 DS tab q6h, or 2 DS tabs q12h |
||
|- |
|- |
||
| 45-49 |
| 45-49 |
||
− | | 15 mL q8h |
||
| 720 |
| 720 |
||
+ | | 15 mL q8h |
||
+ | |3 SS tabs q8h |
||
|- |
|- |
||
| 50-69 |
| 50-69 |
||
− | | 15 mL q6h |
||
| 960 |
| 960 |
||
+ | | 15 mL q6h |
||
+ | |2 DS tabs q8h, or 3 SS tabs q6h |
||
|- |
|- |
||
| 70-79 |
| 70-79 |
||
− | | 25 mL q8h |
||
| 1200 |
| 1200 |
||
+ | | 25 mL q8h |
||
+ | |5 SS tabs q8h |
||
|- |
|- |
||
| 80-89 |
| 80-89 |
||
− | | 20 mL q6h |
||
| 1280 |
| 1280 |
||
+ | | 20 mL q6h |
||
+ | |2 DS tabs q6h |
||
|- |
|- |
||
| 90-99 |
| 90-99 |
||
− | | 30 mL q8h |
||
| 1440 |
| 1440 |
||
+ | | 30 mL q8h |
||
+ | |3 DS tabs q8h |
||
|- |
|- |
||
| 100-109 |
| 100-109 |
||
− | | 25 mL q6h |
||
| 1600 |
| 1600 |
||
+ | | 25 mL q6h |
||
+ | |2/2/3/3 DS tabs q6h, or 5 SS tabs q6h |
||
|- |
|- |
||
| 110-119 |
| 110-119 |
||
− | | 35 mL q8h |
||
| 1680 |
| 1680 |
||
+ | | 35 mL q8h |
||
+ | |7 SS tabs q8h |
||
|- |
|- |
||
| 120-129 |
| 120-129 |
||
− | | 30 mL q6h |
||
| 1920 |
| 1920 |
||
+ | | 30 mL q6h |
||
+ | |3 DS tabs q6h |
||
|} |
|} |
||
Line 123: | Line 146: | ||
{| class="wikitable" |
{| class="wikitable" |
||
! Weight (kg) |
! Weight (kg) |
||
+ | ! Total dose TMP (mg/day) |
||
! Dose (IV) |
! Dose (IV) |
||
+ | !Dose (PO) |
||
− | ! Total dose TMP (mg/day) |
||
|- |
|- |
||
| 40-54 |
| 40-54 |
||
+ | | 960 |
||
| 15 mL q6h |
| 15 mL q6h |
||
+ | |2 DS tabs q8h, or 3 SS tabs q6h |
||
− | | 960 |
||
|- |
|- |
||
| 55-69 |
| 55-69 |
||
+ | | 1280 |
||
| 20 mL q6h |
| 20 mL q6h |
||
+ | |2 DS tabs q6h |
||
− | | 1280 |
||
|- |
|- |
||
| 70-79 |
| 70-79 |
||
− | | 30 mL q8h |
||
| 1440 |
| 1440 |
||
+ | | 30 mL q8h |
||
+ | |3 DS tabs q8h |
||
|- |
|- |
||
| 80-89 |
| 80-89 |
||
− | | 25 mL q6h |
||
| 1600 |
| 1600 |
||
+ | | 25 mL q6h |
||
+ | |2/2/3/3 DS tabs q6h, or 5 SS tabs q6h |
||
|- |
|- |
||
| 90-104 |
| 90-104 |
||
− | | 30 mL q6h |
||
| 1920 |
| 1920 |
||
+ | | 30 mL q6h |
||
+ | |3 DS tabs q6h |
||
|- |
|- |
||
| 105-119 |
| 105-119 |
||
− | | 35 mL q6h |
||
| 2240 |
| 2240 |
||
+ | | 35 mL q6h |
||
+ | |3/3/4/4 DS tabs q6h, or 7 SS tabs q6h |
||
|- |
|- |
||
| 120-134 |
| 120-134 |
||
− | | 40 mL q6h |
||
| 2560 |
| 2560 |
||
+ | | 40 mL q6h |
||
+ | |4 DS tabs q6h |
||
|} |
|} |
||
Line 184: | Line 215: | ||
== Adverse Drug Reactions == |
== Adverse Drug Reactions == |
||
+ | * Systemic allergic reactions |
||
− | * Allergic reactions, including [[Adverse drug reaction::anaphylaxis]] and a relatively high rate of [[Adverse drug reaction::SJS]]/[[Adverse drug reaction::TEN]] |
||
+ | **[[Adverse drug reaction::Anaphylaxis]] |
||
+ | **[[Adverse drug reaction::Serum sickness]] |
||
+ | *Cutaneous reactions |
||
+ | **High rate of [[Adverse drug reaction::SJS]]/[[Adverse drug reaction::TEN]] |
||
+ | **Other non-specific rash |
||
+ | **[[Adverse drug reaction::Erythema multiforme]] |
||
+ | **[[Adverse drug reaction::Urticaria]] |
||
+ | **[[Adverse drug reaction::Photodermatitis]] |
||
* [[Adverse drug reaction::GI upset]], including nausea at higher doses |
* [[Adverse drug reaction::GI upset]], including nausea at higher doses |
||
* [[Adverse drug reaction::Drug-drug interactions]] |
* [[Adverse drug reaction::Drug-drug interactions]] |
||
− | ** Increases warfarin levels |
+ | ** Increases [[warfarin]] levels |
* [[Adverse drug reaction::Anemia]], [[Adverse drug reaction::neutropenia]] and [[Adverse drug reaction::thrombocytopenia]] |
* [[Adverse drug reaction::Anemia]], [[Adverse drug reaction::neutropenia]] and [[Adverse drug reaction::thrombocytopenia]] |
||
** It is a mild folate antagonist |
** It is a mild folate antagonist |
||
* [[Adverse drug reaction::Hepatotoxicity]] |
* [[Adverse drug reaction::Hepatotoxicity]] |
||
* [[Adverse drug reaction::Hyperkalemia]] |
* [[Adverse drug reaction::Hyperkalemia]] |
||
+ | *[[Adverse drug reaction::Hyponatremia]] |
||
* [[Adverse drug reaction::Hypoglycemia]] |
* [[Adverse drug reaction::Hypoglycemia]] |
||
* [[Adverse drug reaction::Acute kidney injury]], though it also increases tubular creatinine reabsorption |
* [[Adverse drug reaction::Acute kidney injury]], though it also increases tubular creatinine reabsorption |
Latest revision as of 10:00, 30 March 2022
Background
- Sulfonamide antibiotic
Brand Names
- Septra
- Bactrim (US)
- TMP-SMX
Dosing
- Traditionally based on the trimethroprim component
Form | TMP | SMX | Conversion |
---|---|---|---|
Intravenous | 16 mg/ml | 80 mg/ml | 10 mL |
Oral suspension | 8 mg/ml | 40 mg/ml | 20 mL |
Oral SS tab | 80 mg | 400 mg | 2 tabs |
Oral DS tab | 160 mg | 800 mg | 1 tab |
- Resistant Gram-negative infections
- Cystitis: 160 mg (1 SS tab) IV/PO q12h
- Other infections: 8 to 12 mg/kg/day IV/PO divided q8-12h (max 960 mg total daily dose)
- Nocardia: 10 mg/kg TDD
- Pneumocystis jirovecii: 15-20 mg/kg TDD
- CNS infections: 15-20 mg/kg TDD
Oral Dosing
- Ranges from 1 SS tab BID (160 mg TMP TDD) to 3 DS tabs TID (1440 mg TMP TDD)
Intravenous Dosing
- 10 to 20 mg/kg TMP total daily dose, split TID to QID
TMP 10 mg/kg per day
Weight (kg) | Total dose TMP (mg/day) | Dose (IV) | Dose (PO) |
---|---|---|---|
40-49 | 480 | 10 mL q8h | 1 DS tab q8h |
50-64 | 640 | 10 mL q6h | 1 DS tab q6h, or 2 DS tabs q12h |
65-74 | 720 | 15 mL q8h | 3 SS tabs q8h |
75-99 | 960 | 15 mL q6h | 2 DS tabs q8h, or 3 SS tabs q6h |
100-129 | 1280 | 20 mL q6h | 2 DS tabs q6h |
TMP 15 mg/kg per day
Weight (kg) | Total dose TMP (mg/day) | Dose (IV) | Dose (PO) |
---|---|---|---|
40-44 | 640 | 10 mL q6h | 1 DS tab q6h, or 2 DS tabs q12h |
45-49 | 720 | 15 mL q8h | 3 SS tabs q8h |
50-69 | 960 | 15 mL q6h | 2 DS tabs q8h, or 3 SS tabs q6h |
70-79 | 1200 | 25 mL q8h | 5 SS tabs q8h |
80-89 | 1280 | 20 mL q6h | 2 DS tabs q6h |
90-99 | 1440 | 30 mL q8h | 3 DS tabs q8h |
100-109 | 1600 | 25 mL q6h | 2/2/3/3 DS tabs q6h, or 5 SS tabs q6h |
110-119 | 1680 | 35 mL q8h | 7 SS tabs q8h |
120-129 | 1920 | 30 mL q6h | 3 DS tabs q6h |
TMP 20 mg/kg per day
Weight (kg) | Total dose TMP (mg/day) | Dose (IV) | Dose (PO) |
---|---|---|---|
40-54 | 960 | 15 mL q6h | 2 DS tabs q8h, or 3 SS tabs q6h |
55-69 | 1280 | 20 mL q6h | 2 DS tabs q6h |
70-79 | 1440 | 30 mL q8h | 3 DS tabs q8h |
80-89 | 1600 | 25 mL q6h | 2/2/3/3 DS tabs q6h, or 5 SS tabs q6h |
90-104 | 1920 | 30 mL q6h | 3 DS tabs q6h |
105-119 | 2240 | 35 mL q6h | 3/3/4/4 DS tabs q6h, or 7 SS tabs q6h |
120-134 | 2560 | 40 mL q6h | 4 DS tabs q6h |
Renal Dosing
CrCl (mL/min) | Bacterial infection (TMP) | PJP (TMP) |
---|---|---|
> 30 | 8-12 mg/kg/day in 2-4 divided doses | 15-20 mg/kg/day in 2-4 divided doses |
10 to 29 | 75% of usual dose | 12-15 mg/kg/day in 2-4 divided doses |
< 10, including PD | Generally not recommended; use 50% of usual dose | Generally not recommended; use 7.5-10 mg/kg/day in 2-4 divided doses |
Hemodialysis | 50% of usual dose, scheduled post-dialysis | 50% of usual dose, scheduled post-dialysis |
CRRT | 7.5 mg/kg/day in 2-4 divided doses | 15 mg/kg/day in 2-4 divided doses |
Adverse Drug Reactions
- Systemic allergic reactions
- Cutaneous reactions
- High rate of SJS/TEN
- Other non-specific rash
- Erythema multiforme
- Urticaria
- Photodermatitis
- GI upset, including nausea at higher doses
- Drug-drug interactions
- Increases warfarin levels
- Anemia, neutropenia and thrombocytopenia
- It is a mild folate antagonist
- Hepatotoxicity
- Hyperkalemia
- Hyponatremia
- Hypoglycemia
- Acute kidney injury, though it also increases tubular creatinine reabsorption
- Renal tubular acidosis
Further Reading
- Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183(16):1851-1858. doi: 10.1503/cmaj.111152
- Review of adverse events